Lipocine(LPCN) - 2023 Q2 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended June 30, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Delaware 99-0370688 (State or Other Jurisdiction of Incorporation or Organization) For the transition period from to . 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108 (Address of Principal Executive ...